MY-5445

Research use only, not for human use.

MY-5445 is a specific inhibitor of phosphodiesterase type 5 (PDE5). MY-5445 selectively inhibits cGMP PDE (Ki:1.3 μM).

MY-5445 is a specific inhibitor of phosphodiesterase type 5 (PDE5). MY-5445 selectively inhibits cGMP PDE (Ki:1.3 μM).(In Vitro): in ABCG2-overexpressing cells, MY-5445 selectively reverses ABCG2-mediated multidrug resistance. MY-5445 reverses ABCG2-mediated multidrug resistance (MDR) by potentiating the cytotoxicity of an ABCG2 substrate drug in ABCG2-overexpressing multidrug-resistant cancer cells, possibly by modulating the function and/or the protein expression of ABCG2. In the S1-M1-80 cell, MY-5445 (3 μM; 48 hours) substantially increases the topotecan-induced apoptosis.(In Vivo):I.p administration of 0.5-3 mg/kg twice a day for 15 days) produces significant relief of mechanical hypersensitivity.

N-(3-chlorophenyl)-4-phenylphthalazin-1-amine

Angiogenesis

PDE

DHFR

——

——

78351-75-4

331.8

C20H14ClN3

>98% (HPLC)

——

Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1

——

(-20℃)

With Ice Pack

≥ 2 years